HARMONY BIOSCIENCES SHOWCASES THE NEWEST PATIENTS AT THE HEART AND PROGRESS AT THE HEART AWARD RECIPIENTS

Rhea-AI Summary

Harmony Biosciences Holdings, Inc. has selected new nonprofit organizations for its Patients at the Heart and Progress at the Heart awards, providing funding support for initiatives addressing sleep disorders and rare neurological diseases. The initiatives aim to enhance care, education, and awareness for patients, caregivers, and professionals. The company is dedicated to supporting transformation within these communities.

Positive

• Harmony Biosciences has selected new nonprofit organizations for its Patients at the Heart and Progress at the Heart awards, providing funding support for initiatives addressing sleep disorders and rare neurological diseases. The initiatives aim to enhance care, education, and awareness for patients, caregivers, and professionals. This commitment to supporting these communities can positively impact the company's reputation and investor sentiment.

Negative

• None.

PLYMOUTH MEETING, Pa., Oct. 26, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, has selected the latest round of nonprofit organizations for its Patients at the Heart and Progress at the Heart awards. These awards provide funding support to nonprofit organizations addressing the complex challenges affecting individuals with sleep disorders and rare neurological diseases through unique and impactful initiatives.

Over the past four years, Patients at the Heart has supported 24 initiatives aimed at addressing the comprehensive needs of individuals and their families affected by sleep disorders and rare neurological diseases. The newest awardees include the following organizations:

Awareness & Patient Support Progression – Kleine-Levin Syndrome Foundation
This initiative builds educational and support resources for people with Kleine-Levin syndrome (KLS) and the broader scientific community by creating a new ambassador program that connects patients, caregivers, educators, and professionals to enhance care. 

"KLS is an exceptionally rare neurological disorder, affecting only one in a million individuals worldwide, primarily adolescents, and is characterized by episodes of excessive sleep, altered behavior, and a diminished understanding of the world," said Dani Farber, VP of the Kleine-Levin Syndrome Foundation. "With support from a previous Patients at the Heart award, we achieved the 'Strategic Communications for Awareness' project, which fortified and expanded our patient registry and outreach endeavors. Building on this success, our 'KLS Awareness and Patient Support Progression' initiative will enhance resources for education, raise awareness, and establish a KLS ambassadorship program that will provide crucial support to patients, caregivers, educators, and professionals alike."

PWS Sleep Within Reach Resources – Prader-Willi Syndrome Association | USA
This program educates health care professionals, caregivers of people with Prader-Willi syndrome (PWS), as well as residential and educational staff on the most misunderstood forms of sleep disorders, including those among people with PWS.

"We are honored to be recognized with a Patients at the Heart award for our 'Reach Resources' program, which provides free, multi-tiered support to individuals living with and affected by PWS," said Stacy Ward, MS, Interim CEO of the Prader‐Willi Syndrome Association | USA. "This initiative underscores our commitment to fostering collaborative care, involving professionals, caregivers, and educational staff. Through project elements like 'PWS ECHO Sleep Within Reach' and 'ECHO Debrief,' alongside the development of educational toolkits, we reaffirm our dedication to making a meaningful impact in the lives of those affected by this rare and challenging condition, as well as their loved ones."

Progress at the Heart provides funding support for novel initiatives addressing disparities, injustices, and inequities in rare neurological disease and sleep disorder communities. In the two years since it started, it has supported 15 initiatives, including the newest recipients:

The Restful Revolution – Rare & Black
The Restful Revolution, an innovative pilot program, will provide support to up to five Historically Black Colleges and Universities in the Washington, DC and Baltimore area for the 2023-2024 academic school year. Its mission is to educate and empower students to cultivate healthy sleep habits and raise awareness about sleep disorders.

"For far too long, the sleep health of students at Historically Black Colleges and Universities and institutions with significant Black student populations has been unjustly overlooked," said Dionne L. Stalling, Founder of Rare & Black. "This innovative program marks an important step forward. In the upcoming academic year, we will visit up to five institutions in the Washington, DC, and Baltimore area, equipping students with essential sleep habits and shedding light on the challenges of sleep disorders. Together, with this funding support, we can create a future where every student's overall well-being, particularly those from historically underserved communities, takes equal precedence."

Wake Up and Learn – Geisinger Health Foundation
Wake Up and Learn is a virtual K-12 educational and surveillance program that facilitates a culture shift towards a valuation of sleep as essential for health and removing barriers to timely recognition, diagnosis, and management of sleep disorders in school-aged children. The 2024 program will expand the video curriculum, translate materials into Spanish, and assess impact through interviews with a focus on diverse geographic, ethnic and gender perspectives.

"We are facing a critical issue of sleep-wake disorders in the US, affecting a significant portion of the population, including many students," said Anne Marie Morse, DO, a board-certified and fellowship-trained pediatric neurologist and sleep medicine specialist at Geisinger Health System. "Racial and economic disparities worsen this dire situation, leading to limited access to care and heightened stigma, particularly in historically underserved communities. Our latest effort, Wake Up and Learn, introduces a transcultural, school-based program emphasizing the importance of sleep for students' well-being and their potential in life. Through this initiative, we seek to emphasize the crucial role of sleep in their journey to success and urge greater attention to recognizing poor sleep and addressing it promptly."

Harmony is dedicated to supporting significant transformation within the rare neurological disease and sleep disorder communities. The next call for Patients at the Heart and Progress at the Heart award nominations will be announced next year. 

"Our Patients at the Heart and Progress at the Heart awards exemplify our commitment to empathy and innovation, catalyzing our commitment to these nonprofit organizations who are leading the way in addressing complex challenges posed by sleep and rare neurological disorders," said Cate McCanless, Chief Corporate Affairs Officer at Harmony Biosciences. "We are honored to support these initiatives, which collectively hold the potential to make a lasting impact on individuals and communities facing significant unmet needs, while always placing patients at the heart of everything that we do."

To learn more about Patients at the Heart, please visit: https://www.harmonybiosciences.com/funding-programs/patients-at-the-heart/.

To learn more about Progress at the Heart, please visit: https://www.harmonybiosciences.com/funding-programs/progress-at-the-heart/.

About Harmony Biosciences
At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com.

Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com 

Harmony Biosciences Investor Contact:
Luis Sanay, CFA
445-235-8386
lsanay@harmonybiosciences.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-showcases-the-newest-patients-at-the-heart-and-progress-at-the-heart-award-recipients-301968748.html

SOURCE Harmony Biosciences

FAQ

What are the Patients at the Heart and Progress at the Heart awards?

The Patients at the Heart and Progress at the Heart awards are initiatives by Harmony Biosciences that provide funding support for nonprofit organizations addressing sleep disorders and rare neurological diseases.

What is the purpose of these initiatives?

The initiatives aim to enhance care, education, and awareness for patients, caregivers, and professionals in the sleep disorder and rare neurological disease communities.

How can these initiatives impact Harmony Biosciences?

By supporting these initiatives, Harmony Biosciences can enhance its reputation and investor sentiment, as well as contribute to the transformation of the sleep disorder and rare neurological disease communities.